April 19, 2016 — Toshiba America Medical Systems Inc.’s Aquilion Lightning computed tomography (CT) system was U.S. Food ...

April 20, 2016 — A competition that used technology to encourage and track physical activity was effective at helping ...

In the first large randomized trial to directly compare two approaches to preventing atrial fibrillation following heart surgery, controlling heart rate and controlling heart rhythm performed equally well.

In one of the largest trials ever conducted of heart failure patients with reduced ejection fraction, the investigational drug aliskiren failed to show superiority over full-dose treatment with the existing “gold standard” therapy angiotensin-converting enzyme (ACE) inhibitor enalapril.

A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation myocardial infarction (STEMI) failed to show the procedure significantly reduces death from any cause or hospitalization for heart failure.

Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest form of heart attack, ST-segment elevation myocardial infarction (STEMI), according to research presented at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16).

The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral arterial disease (PAD) treatment recommendations to the Medicare Evidence Development Coverage Advisory Committee (MEDCAC).